Maelor plc, the specialist critical care pharmaceuticals and devices

Volplex A 4% solution of succinylated gelatin used in operating theatres and wards in patients who require fluid replacement.
OptiFlo UK brand of a range of catheter irrigation solutions.
ContiSol international brand of a range of catheter irrigation solutions.

Development products

Micelle nanotechnology - A drug delivery system which enables insoluble active pharmaceuticals to be solubilised.
Lead development products in this area relate to:
* Interstitial cystitis and chronic pelvic pain (Plethora Solutions)
* Wound care
* Anaesthesiology

Operational highlights announced 1 June 2006

Licensing agreement with Plethora Solutions plc for micelle nanotechnology drug delivery system for use in the treatment of interstitial cystitis and painful bladder syndrome
Volplex UK rights re-acquired and product re-launched successfully. In-market sales for the second half of the year up 35% compared to the first half compared to the first half
OptiFlo UK in-market sales grow by 32% over the previous year
Jump 17%
http://www.maelor.plc.uk

10 May 2007 - Acquisition of Acorus Therapeutics Ltd completed

24 Feb 2004 - signed a major contract for the distribution of
its plasma substitute product,Volplex, in China. The agreement with Helicon Group
Pty Ltd will lead to Volplex being marketed and distributed in China through a network
of sales offices. Helicon is also charged with the regulatory submission, which should
be completed in 2004.

Volplex (succinylated gelatin) is given as an intravenous infusion to substitute
for blood volume lost by patients suffering from the effects of trauma, surgery
or certain medical conditions which result in hypovolaemia (lower than normal
blood volume).

Volplex has expanded its international franchise over the last few months,
gaining regulatory approval in Argentina in December 2003 where it will shortly
be launched. Maelor has established partners in South Africa and Bangladesh
(where regulatory applications have already been submitted) and also in
Australia in preparation for future launches in those markets.

Pretty damn quiet.....has the lack of newsflow made us silent?

Well, I bought some at just under 11p. At today's price the investment risk is pretty small and the up-side remains as -ever.
Oddly, my purchase was recorded as a sale, in Trades-section.

No significant improvement in the sp but maybe (just) they are getting to grips with costs and (might) soon produce a profit. In that case the sp can be valued and one would hope that the profit might be slightly ahead.
Presently, turnover is almost the same as loss - so for every order they ship the loss increases by the same amount. Really does look as though Management hasn't really got to grips with the business.
The good thing, however, is they aren't a 1-product company - phew, that's OK then? Well, maybe.
( Annual accounts just received, hence the mind playing tricks)
Pity the AGM is in Wrexham, N Wales. Shan't be going and I doubt if many others will either.

So whats going on here... 1.75p rise... from 10p today morning to 11.75! and plenty of crazy buying continues.....

Speculative punt at these levels.

Market cap 3mil.

Cash balances half of market cap and they have increased lately.

Chairmans last statement :

Commenting on the results Chairman, Alastair Macpherson, said:

'These results, with strong revenue growth and sharply reduced losses, show that
Maelor is on track for profitability. With our two lead products continuing to
take market share and our products entering new territories, we expect to
continue to build on the substantial growth which we have achieved over the past
three years.'

There's a lot lot worse companies out there valued at 3mil.

Others seem to agree, 150k buys today and very little
selling but no move which is surprising.

Cannot believe there was not even one trade today !

The stock should be trading higher than 10p given their
strong cash position and long term prospects.

Thinking about going in on this one... now showing signs of recovery ? anyone any news & views?

Bought in this morning at 11.38p... onwards and upwards...no target in mind but would settle for 50% rise in next few months or 100% in a year!

We should ee some interesting annoucements and progress within the next few months. Definately an undervalued find and a serious consideration for any portfolio.

Totally new progressive management team looking to exapnd on MLR's traditional territory

I'm staying in and hoping for the best... might even top up at these levels !

Anyone know what's brewing ? sp is moving up fast-ish...
Now half way back to my breakeven price.

This looks to me like a lunchtime rise, caused by the mm's, due to fall back after 2.00pm

Scotland on Sunday-17Sept
Maelor looks healthy
PERRY GOURLEY

SHARES in healthcare group Maelor, which specialises in drugs and devices for patients in intensive care, appear to be showing signs of moving off the critical list themselves.

Last month they hit an all-time low of under 6p compared to the highs of over 120p seen five years ago.

But since then investors have been told that current trading was encouraging and it was making good progress with its new strategy. Its AGM heard that the board was "looking forward to the future with confidence" and a series of deals by the top men at the company appears to confirm that.

On September 8, chairman Geoff McMillan bought 200,000 at 6.6p and three days later chief executive Tim Wright bought 450,000 shares at 7p. Although the amount spent by the two hardly implies they are putting their houses on the line, they have each significantly increased their holdings. McMillan now holds 500,000 shares and Wright 450,000.

slmchow... good info... thanks... just need a bit of patience with this one to reap the rewards...

Looking good.... from the Sunday Times article...

"I have reinvested the cash, and a bit more, in a tiny healthcare firm called Maelor. This is a turnround play. Historically, Maelor had eggs in too many baskets. But new management came in a year ago, axed an expensive drug project and decided to focus on critical-care products. Only the house broker, Numis, gives it any coverage.

With a market value of only 3m and 1m in cash, there is all to play for. The chief executive, Tim Wright, has done it all before; he built the European operation of the Irish pharma giant, Elan Corporation, from nothing to a business with a 100m turnover. He and other directors bought 1.25m shares in Maelor last month, paying between 6.625p and 8p a share. Coming only three weeks before the company enters its closed period ahead of results when no director can deal that is a positive signal if ever there were one."

Results in about 3 months time

Anyone interested on the report by Lewis Charles Securities on Maelor dated 02/11/06 can go here

http://www.lewischarles.com/

Click on then , accept the legal disclaimer, then scroll down to . The report you want is the only one available at present.

Note: you will have to set your browser to accept pop-ups to be able to access the report.

looks like a nice little earner eh 'enry!

Anyone else in MLR ?

This from yesterday's Peter Shearlocks Small Cap Stock Picks

Transforming deal for Maelor

I tipped critical care products business Maelor last September (at 6.5p) for one reason only: its management had form for building a big pharma business from scratch. That faith appears to have been well placed. Maelor has now achieved a transforming deal with the acquisition of Acorus Therapeutics for up to 13 million. Acorus is in similar areas of neurology and critical care with products that have either been launched on the market or are at a late stage in their development therefore representing low-risk investments.

The deal transforms Maelors profit and loss account. In a trading statement on Thursday it said the final quarter of the year had sustained the upturn noted in the half-year statement and losses would be significantly below expectations. The blood plasma substitute Volplex is clearly still gaining market share. Together with Acorus, which is highly profitable, it looks as if the enlarged Maelor should make a profit of somewhere well over 1 million this year.

To help fund the deal, Maelor placed 80 million new shares at 10p on Thursday, lifting the number of shares in issue to 125 million. With the shares trading at 13.25p after the deal, that puts a value of 16.6 million on the company. There is clearly still a fair amount of upside. Continue to hold. I am a shareholder in Maelor.

After today's EGM I would expect to see some good press over the weekend as this appears to be a star in the making.

Now well in profit after the reverse takeover and with an easily manageable debt and good income flow this should be an interesting, and profitable ride, for the asute punter.

been in for a while now at 11pish so looking fwd to good times